Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:37:36.607Z.
Calculation as of: 2026-10-06T20:37:36.607Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 733e4da94f9494cd21c7af02f5120fd8528014c079e3dffba0957966aae51245
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NextCure, Inc. (NXTC) | $20.53M | N/A | N/A | N/A | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $19.77M | N/A | N/A | N/A | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.42M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | N/A | N/A | N/A | N/A |
| Modular Medical, Inc. (MODD)vs › | $22.25M | N/A | N/A | N/A | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.65M | N/A | 2.38 | 2.38 | 2.38 |
| P3 Health Partners Inc. (PIII)vs › | $18.41M | N/A | N/A | N/A | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.68M | N/A | N/A | N/A | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.30M | N/A | N/A | N/A | N/A |
| Rein Therapeutics Inc. (RNTX)vs › | $23.06M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$5.68
Forward EPS (Est.)
$-6.34
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
